삼성제약
001360 · KOSPI삼성제약(주) · SAMSUNG PHARMACEUTICAL.CO.,Ltd.
Market data
삼성제약 · 001360 · KOSPIPrevious-close data, updated T+1 · Source: Financial Services Commission of Korea via data.go.kr
Key financials
| Year | Revenue | Op. profit | Net income | Debt ratio |
|---|---|---|---|---|
| 2025 separate | ₩46.1B +4.0% | -₩18.1B | ₩11.5B | 38.3% |
| 2024 separate | ₩44.3B -14.7% | -₩14.8B | -₩14.1B | 21.4% |
| 2023 separate | ₩52.0B | -₩18.0B | -₩24.8B | 20.5% |
Annual summary statements · Source: Financial Services Commission of Korea via data.go.kr
BullBear analysis record
1 related article in 30 days — Bull 0 · Bear 0 · Mixed 1
AI note
Samsung Pharmaceutical (001360) remains an ongoing business on the KOSPI. As of September 1 2026, its shares closed at 1,362 KRW, up 2.87% from the previous day. For 2025, the company reported revenue of about 46.1 billion KRW, a 4.0% year‑over‑year increase, but an operating loss of roughly 18.1 billion KRW, while net income was 11.5 billion KRW and the debt ratio stood at 38.3%. BullBear’s analysis identified one mixed article about the company in the past 30 days.
AI-generated from the data above (2026-09-03). Not investment advice.